Genentech has reported encouraging preliminary results from a Phase IItrial testing its recombinant humanized monoclonal antibody against immunoglobulin E, E25, in adults and adolescents with moderate to severe asthma. The company, with partners Novartis and Tanox Biosystems, have agreed that these results support the continued development of E25 in Phase III trials for the treatment of allergic asthma and allergic rhinitis.
This was welcome good news for the biotechnology firm, which earlier this month announced that it was dropping one of its key programs, insulin-like growth factor-1 for diabetes mellitus (Marketletter September 15).
In the randomized placebo-controlled trial, 317 moderate-to-severe allergic asthmatics were enrolled at 27 sites across the USA. Patients were monitored for daily symptoms over a five-month treatment period. E25 was given by subcutaneous injection at several timepoints during the treatment phase, but the company will not divulge the actual protocol or results until later this year at the annual meeting of the American College of Allergy, Asthma and Immunology, which will be held in San Diego on November 7-12.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze